Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| WLK | PRESS-RELEASE | neutral | 1/10 | Westlake Corporation announced it will host a conference call on August 4, 2026 to discuss its Q2 2026 results. | Jul 21, 2026 |
| RNTX | PRESS-RELEASE | neutral | 3/10 | Rein Therapeutics announced that its Phase 2 RENEW trial for inhaled LTI-03 in IPF is now open in Germany, completing th | Jul 21, 2026 |
| HELP | PRESS-RELEASE | neutral | 5/10 | Helus Pharma completed enrollment in the APPROACH Phase 3 pivotal study of HLP003 for Major Depressive Disorder (MDD) ah | Jul 21, 2026 |
| RZLT | PRESS-RELEASE | neutral | 2/10 | Rezolute announced management participation in the BTIG Virtual Biotechnology Conference on July 28-29, 2026. This is a | Jul 21, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics subsidiary CNSide Diagnostics signed a regional agreement with Medical Mutual covering ~1.2M members i | Jul 21, 2026 |
| TPST | PRESS-RELEASE | neutral | 5/10 | Tempest Therapeutics announced a strategic partnership with Hebei Senlang Biotechnology to develop TPST-4003, an in vivo | Jul 21, 2026 |
| INSM | ANALYST-UPGRADE | bullish | 4/10 | BMO Capital initiated coverage on INSM at Outperform with a $192 price target, implying 78.6% upside from the current $1 | Jul 21, 2026 |
| JUNS | PRESS-RELEASE | bullish | 7/10 | Jupiter Neurosciences licensed exclusive U.S. rights to ALA-002, an FDA-designated Novel Chemical Entity (non-racemic MD | Jul 21, 2026 |
| INCY | CLUSTER | neutral | 2/10 | Two senior Incyte executives (CMO and EVP of U.S. Commercial) sold a combined $341K in open-market stock on July 16, 202 | Jul 21, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | A cluster of insider sales at United Therapeutics shows the CEO and General Counsel selling shares, primarily to cover t | Jul 21, 2026 |
| MLYS | CLUSTER | neutral | 3/10 | CEO Jon Congleton and CMO David Malcom Rodman sold a combined ~$302K in MLYS stock over a 7-day window, with the CEO's $ | Jul 20, 2026 |
| JSPR | 3 | neutral | 3/10 | Patrick J. Crutcher filed a Form 3 initial statement of beneficial ownership, disclosing 518,331 shares of voting common | Jul 20, 2026 |
| JAZZ | PRESS-RELEASE | neutral | 1/10 | Jazz Pharmaceuticals plc announced it will report its Q2 results on August 3, 2026. | Jul 20, 2026 |
| IFF | PRESS-RELEASE | neutral | 3/10 | SuanNutra (IFF) filed a press release categorized as M&A. The document content was unavailable due to a 404 error, so no | Jul 20, 2026 |
| ADPT | CLUSTER | neutral | 2/10 | Two C-suite officers at Adaptive Biotechnologies sold a combined $2.5M in open-market sales over a 7-day window. The tot | Jul 20, 2026 |
| TLX | PRESS-RELEASE | bullish | 6/10 | Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects | Jul 20, 2026 |
| ARTV | INSIDER-BUY | bullish | 7/10 | RA Capital Management, a 10% owner and director, purchased $1.56M in ARTV stock over a week, including a $1.36M block on | Jul 20, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted stock options and RSUs to one newly hired non-executive employee as an inducement under Nasd | Jul 20, 2026 |
| CBIO | INSIDER-BUY | bullish | 7/10 | Director and 10% owner Fairmount Funds Management LLC made a $12.38M open-market purchase of 853,450 CBIO shares at $14. | Jul 20, 2026 |
| ASBP | 8-K | neutral | 2/10 | Aspire Biopharma filed an 8-K to clarify the terms of its public warrants (ASBPW) following two reverse stock splits. Th | Jul 20, 2026 |
| OMER | 8-K | bullish | 5/10 | Omeros repurchased and retired $30.5 million aggregate principal amount of its 9.50% Convertible Senior Notes due 2029 i | Jul 20, 2026 |
| TLX | PRESS-RELEASE | bullish | 4/10 | Telix Pharmaceuticals announced the first patient dosed in its Phase 3 LUTEON1 trial evaluating TLX250-Tx, a CAIX-target | Jul 20, 2026 |
| DMRA | 8-K | neutral | 3/10 | Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026, as appro | Jul 20, 2026 |
| CMND | 6-K | neutral | 2/10 | Clearmind Medicine filed a patent application in Hong Kong for novel psychedelic compounds targeting PTSD, expanding its | Jul 20, 2026 |
| GRML | CLUSTER | bullish | 6/10 | Two insiders at Greenland Mines Ltd (GRML) purchased a combined $270K in open-market transactions over a 7-day window, l | Jul 20, 2026 |
| TEVA | INST-CLUSTER | bullish | 5/10 | A bullish institutional cluster formed in TEVA during 2026-Q2, with four asset managers adding $400.6M in net new holdin | Jul 20, 2026 |
| VNRX | EFFECT | bearish | 6/10 | VolitionRx's S-3 shelf registration became effective on July 17, 2026, allowing selling stockholders to immediately rese | Jul 20, 2026 |
| TOMZ | PRESS-RELEASE | neutral | 3/10 | TOMI Environmental Solutions issued a press release providing an update on Carbonium Core's business, referencing the pr | Jul 20, 2026 |
| IMMX | 8-K | neutral | 1/10 | Immix Biopharma filed an 8-K reporting the termination of Richard Graydon effective July 17, 2026, for reasons unrelated | Jul 20, 2026 |
| RMTI | 8-K | neutral | 2/10 | Rockwell Medical announced it has regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) afte | Jul 20, 2026 |